Literature DB >> 32445275

A pathogenic variant in the SETBP1 hotspot results in a forme-fruste Schinzel-Giedion syndrome.

Jennifer A Sullivan1, Nicholas Stong2, Evan H Baugh2, Marie T McDonald1, Akihito Takeuchi3, Vandana Shashi1.   

Abstract

Schinzel-Giedion syndrome (SGS; OMIM 269150) is an ultra-rare genetic disorder associated with a distinctive facial gestalt, congenital malformations, severe intellectual disability, and a progressive neurological course. The prognosis for SGS is poor, with survival beyond the first decade rare. Germline, de novo heterozygous variants in the SETBP1 gene cause SGS with the pathogenic variants associated with the SGS phenotype missense and confined to exon 4 of the gene, clustered in a four amino acid (12 bp) hotspot in the SKI homologous region of the SETBP1 protein. We report a patient with a de novo I871S variant within the SKI homologous region, which has been associated with the severe phenotype previously; but our patient has fewer features of SGS and a milder course. This is the first report of a forme-fruste phenotype in a patient with a pathogenic variant within the SGS hotspot on the SETBP1 gene and it highlights the importance of considering atypical clinical presentations in the context of severe ultra-rare genetic disorders.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990SETBP1; SETBP1; Schinzel-Giedion syndrome

Mesh:

Substances:

Year:  2020        PMID: 32445275     DOI: 10.1002/ajmg.a.61630

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  2 in total

1.  Detection of a novel SETBP1 variant in a Chinese neonate with Schinzel-Giedion syndrome.

Authors:  Hansong Yang; Zhiyong Liu; Dongmei Chen; Weiru Lin; Lin Wang; Tianfeng Chen; Ruiquan Wang; Xialin Yan
Journal:  Front Pediatr       Date:  2022-09-06       Impact factor: 3.569

2.  Prenatal diagnosis and molecular cytogenetic characterization of an inherited microdeletion of 18q12.3 encompassing SETBP1.

Authors:  Yaqing Zhou; Yan Quan; Yijun Wu; Yinxing Zhang
Journal:  J Int Med Res       Date:  2022-09       Impact factor: 1.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.